Malaria vaccine: Roadblocks and possible solutions

Brazilian Journal of Medical and Biological Research

Volumn 31, Issue 3, 1998, Pages 317-332

  Soares, I S ^a,b   Rodrigues, M M ^b  

^a FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Immunity; Infectious disease; Malaria; Plasmodium; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; HYBRID PROTEIN; INSECTICIDE; LIPOPOLYSACCHARIDE; MALARIA VACCINE; MEMBRANE PROTEIN; PHOSPHORYL LIPID A; PLASMID DNA; RECOMBINANT DNA; RECOMBINANT PROTEIN; SAPONIN; SYNTHETIC PEPTIDE;

DRUG DEVELOPMENT; DRUG RESISTANCE; GENE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LIFE CYCLE; MALARIA; NONHUMAN; PLASMODIUM; REVIEW; T LYMPHOCYTE; VACCINATION; VECTOR CONTROL;

EID: 0031948494     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X1998000300002     Document Type: Review

References (69)

1. Alonso PL, Lindsay SW, Armstrong JRM, Conteh M, Hill AG, David PH, Fegan G, De Francisco A, Hall AJ, Shenton FC, Cham K & Greenwood BM (1991). The effect of insecticide-treated bed nets on mortality of Gambian children. Lancet. 337: 1499-1502.
2. Baruch DI, Pasloske BL, Singh HB, Bi X, Ma XC, Feldman M, Taraschi TF & Howard RJ (1995). Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell, 82: 77-87.
3. Su X-Z, Heatwole VM, Wertheimer SP, Guinet F, Herrfeldt JA, Ravetch JA & Wellems TE (1995). The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell, 82: 89-100.
4. Smith JD, Chitnis CE, Craig AG, Roberts DJ, Hudson-Taylor DE, Peterson DS, Pinches R, Newbold CI & Miller LH (1995). Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell, 82: 101-110.
5. Nussenzweig RS & Long CA (1994). Malaria vaccines: multiple targets. Science, 265: 1381-1383.
6. Nussenzweig V & Nussenzweig RS (1989). Rationale for the development of an engineered sporozoite malaria vaccine. Advances in Immunology, 45: 283-334.
7. Nardin EH & Nussenzweig RS (1993). T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annual Review of Immunology, 11: 687-727.
8. Howard RJ & Pasloske BJ (1993). Target antigens for asexual malaria vaccine development. Parasitology Today, 9: 369-372.
9. Bouharoun-Tayoun HP, Attanath P, Sabchareon A, Chongsuphajaisid-dhi T & Druilhe P (1990). Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. Journal of Experimental Medicine, 172: 1633-1641.
10. Taylor-Robinson AW, Philips RS, Severn A, Moncada S & Liew FY (1993). The role of TH1 and TH2 cells in a rodent malaria infection. Science, 260: 1931-1934.
11. Foo A, Carter R, Lambros C, Graves P, Quakyi I, Targett GAT, Ponnudurai T & Lewis Jr GE (1991). Conserved and variant epitopes of target antigens of transmission-blocking antibodies among isolates of Plasmodium falciparum from Malaysia. American Journal of Tropical Medicine and Hygiene, 44: 623-631.
12. Premawansa S, Peiris MJS, Lakshman Perera KLR, Ariyaratne G, Carter R & Mendis KN (1990) Target antigens of transmission-blocking immunity of Plasmodium vivax malaria. Journal of Immunology, 144: 436-438.
13. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA & Kaslow DC (1991). Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. Journal of Experimental Medicine, 174: 1203-1208.
14. Duffy PE & Kaslow DC (1997). A novel malaria protein, Pfs 28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infection and Immunity. 65: 1109-1113.
15. Herrington DA, Clyde D, Losonsky G, Cortesia M, Murphy JR, Davis J, Baqar S, Felix AM, Heimer EP, Gillesen D, Nardin E, Nussenzweig RS, Nussenzweig V, Hollingdale MR & Levine MM (1987). Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature, 328: 257-259.
16. Tam J, Clavijo P, Lu Y-A, Nussenzweig V, Nussenzweig R & Zavala F (1990). Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. Journal of Experimental Medicine, 149: 2385-2390
17. Wang R, Charoenvit Y, Corradin G, Porrozzi R, Hunter RL, Glenn G, Alving CR, Church P & Hoffman SL (1995). Induction of protective polyclonal antibodies by immunization with Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. Journal of Immunology, 155: 1637-1641.
18. Nardin EH, Oliveira GA, Calvo-Calle JM & Nussenzweig RS (1995). The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. Advances in Immunology, 60: 105-149.
19. Tanner M, Teuscher T & Alonso PL (1995). Spf66 - the first malaria vaccine. Parasitology Today, 11: 10-13.
20. Herrera S, Herrera MA, Corredor A, Rosero F, Clavijo C & Guerrero R (1992). Failure of a synthetic vaccine to protect Aotus lemurinus against asexual blood stages of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 47: 682-690.
21. Alonso PL, Smith T, Armstrong-Schellenberg JRM, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C, Hurt N, Thomas MC, Lyimo E, Weiss NA, Hayes R, Kitua AY, Lopez MC, Kilama WL, Teuscher T & Tanner M (1994). Randomized trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet, 344: 1175-1181.
22. D'Alessandro U, Leach A, Drakeley CJ, Bennet S, Olaleye BO, Fegan GW, Jawara M, Langerock P, George MO, Targett GAT & Greenwood BM (1995). Efficacy trial of malaria vaccine SPf66 in Gambia infants. Lancet, 346: 462-467.
23. Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Eh Wah Y, Chongsuphajaisiddhi T, Gordon DM, White NJ, Sadoff JC & Heppner DG (1996). Randomised double-blind placebo-controlled trial of Spf66 malaria vaccine in children in northwestern Thailand. Lancet, 348: 701-707.
24. Ferreira MU (1996). Malaria vaccine trials: the missing qualitative data. Immunology and Cell Biology, 74: 301-305.
25. Lopez JA, Roggero MA, Duombo O, Gonzalez JM, Tolle R, Koita O, Arevalo-Herrera M, Herrera S & Corradin G (1996). Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparumcircumsporozoite protein by sera from human donors. American Journal of Tropical Medicine and Hygiene, 55: 424-429.
26. Ménard R, Sultan AA, Cortes C, Altszuler R, van Dijk MR, Janse CJ, Waters AP, Nussenzweig RS & Nussenzweig V (1997). Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature, 385: 336-340.
27. Cerami C, Frevert U, Sinnis P, Takacs B, Clavijo P, Santos MJ & Nussenzweig V (1992). The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell, 70: 1021-1033.
28. Qari SH, Goldman IF, Povoa MM, Oliveira S, Alpers MP & Lal AA (1991). Wide distribution of the variant form of the human malaria parasite Plasmodium vivax. Journal of Biological Chemistry, 266: 16297-16300.
29. Ballou WR, Sherwood JA, Neva FA, Gordon DM, Wirtz RA, Wasserman GF, Diggs CL, Hoffman SL, Hollingdale MR, Hockmeyer WT, Schneider I, Young JF, Reeve P & Chulay JD (1987). Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet, 6: 1277-1281.
30. Alving CR, Koulchin V, Glenn GM & Rao M (1995). Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunological Reviews, 145: 5-31.
31. Huffman SL, Edelman R, Bryan JP, Schneider I, Davis J, Sedegah M, Gordon D, Church P, Gross M, Silverman C, Hollingdale M, Clyde D, Sztein M, Losonsky G, Paparello S & Jones TR (1994). Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. American Journal of Tropical Medicine and Hygiene, 51: 603-612.
32. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heponer DG, Yuan G, Hollingdale M, Slaoui M, Hauser P, Voet P, Sadoff JC & Ballou WR (1995). Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B antigen subunit vaccine. Journal of Infectious Diseases, 171: 1576-1585.
33. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garçon N, Krzych U, Marchand M, Ballou WR & Cohen JD (1997). A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. New England Journal of Medicine, 336: 86-91.
34. Holder AA (1988). The precursor to major merozoite surface antigens: structure and role in immunity. Progress in Allergy, 41: 72-97.
35. Blackman MJ, Heidrich HG, Donachie S, McBridge JS & Holder AA (1990). A single fragment of a malaria merozoite surface protein remains on the parasite during red blood cell invasion and is the target of invasion-inhibiting antibodies. Journal of Experimental Medicine, 172: 379-382
36. Blackman MJ, Ling IT, Nicholls SC & Holder AA (1991). Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Molecular and Biochemical Parasitology, 49: 29-34.
37. Chang SP, Gibson HL, Lee NC, Barr PJ & Hui GS (1992). A carboxyl-terminal fragment of Plasmodium falciparum gp 195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. Journal of Immunology, 149: 548-555.
38. Chappel JA & Holder AA (1993). Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognize the first growth factor-like domain of merozoite surface protein-1. Molecular and Biochemical Parasitology, 60: 303-312.
39. Burns JM, Parke LA, Daly TM, Cavacini LA, Weidanz WP & Long CA (1989). A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii. Journal of Immunology, 142: 2835-2840.
40. Holder AA & Freeman RR (1981). Immunization against blood stage rodent malaria using purified antigens. Nature, 294: 361-366.
41. Siddiqui WA, Tam LQ, Kramer KL, Hui GS, Case SE, Yamaga KM, Chang SP, Chan EB & Kan SC (1987). Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proceedings of the National Academy of Sciences, USA, 84: 3014-3018.
42. Herrera S, Herrera MA, Perlaza BL, Burki Y, Caspers P, Dobeli H, Rotmann D & Certa U (1990). Immunization of Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins. Proceedings of the National Academy of Sciences, USA, 87: 4017-4021.
43. Pasay MC, Cheng Q, Rzepczyk C & Saul A (1995). Dimorphism of the C terminus of the Plasmodium vivax merozoite surface protein 1. Molecular and Biochemical Parasitology, 70: 217-219.
44. Shi YP, Sayed U, Qari SH, Roberts JM, Udhayakumar V, Oloo AJ, Hawley WA, Kaslow DC, Nahlen BL & LaI AA (1996). Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infection and Immunity, 64: 2716-2723.
45. Soares IS, Levitus G, Souza JM, Del Portillo HA & Rodrigues MM (1997). Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infection and Immunity, 65: 1606-1614.
46. Daly TM & Long CA (1993). A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii 17XL merozoite surface protein-1 induces a protective immune response in mice. Infection and Immunity, 61: 2462-2467.
47. Ling IT, Ogun SA & Holder AA (1994). Immunisation against malaria with a recombinant protein. Parasite Immunology, 16: 63-67.
48. Ling IT, Ogun SA & Holder AA (1995). The combined epidermal growth factor-like modules of Plasmodium yoelii merozoite surface protein-1 are required for a protective immune response to the parasite. Parasite Immunology, 17: 425-433.
49. Daly TM & Long CA (1995). The humoral immune response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. Journal of Immunology, 155: 236-243.
50. Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH & Kaslow DC (1995). Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Molecular Medicine, 1: 325-332.
51. Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, Tam LQ, Hashiro CQ, Nikaido CM, Gibson HL, Lee-Ng CT, Barr PJ, Yokota BT & Hui GSN (1996). A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infection and Immunity, 64: 253-261.
52. Burghaus PA, Wellde BT, Hall T, Richards RL, Egan AF, Riley EM, Ripley Ballou WR & Holder AA (1996). Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Infection and Immunity, 64: 3614-3619.
53. Inselburg J, Bathurst IC, Kansopon J, Barr PJ & Rossan RN (1993). Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant. Infection and Immunity, 61: 2048-2052.
54. Charoenvit Y, Mellouk S, Cole C, Bechara R, Leef MF, Sedegah M, Yuan LF, Robey FA, Beaudoin RL & Hoffman SL (1991). Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. Journal of Immunology, 146: 1020-1025.
55. + cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. International Immunology, 3: 579-585.
56. + T cell clones correlates with their levels of expression of adhesion molecules. Journal of Experimental Medicine. 175: 895-905.
57. Rodrigues EG, Zavala F, Eichinger D, Wilson JM & Tsuji M (1997). Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. Journal of Immunology, 158: 1268-1274.
58. Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, Palese P, Nussenzweig RS & Zavala F (1993). Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T cell-mediated protective immunity against malaria. Proceedings of the National Academy of Sciences, USA, 90: 5214-5218.
59. + T and B cell epitopes. Journal of Immunology, 153: 4636-4648.
60. + T cell responses induced by recombinant influenza and vaccinia viruses. Cellular Immunology, 173: 96-107.
61. Kaslow DC, Isaacs SN, Quakyi IA, Gwadz RW, Moss B & Keister DB (1991). Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. Science, 252: 1310-1313.
62. Tine JA, Lanar DE, Smith DM, Wellde BT, Schultheiss P, Ware LA, Kauffman EB, Wirtz RA, de Taisne C, Hui GSN, Chang SP, Church P, Hollingdale MR, Kaslow DC, Hoffman S, Guito KP, Ballou WP, Sadoff JC & Paoletti E (1996). NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infection and Immunity. 64: 3833-3844.
63. Sadoff J, Ballou W, Baron L, Majarian W, Brey R, Hockmeyer W, Young J, Cryz S, Ou J, Lowell G & Chulay J (1988). Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science, 240: 336-338.
64. Gonzales C, Hone D, Noriega FR, Tacket CO, Davis JR, Losonsky G, Nataro JP, Hoffman S, Malik A, Nardin E, Sztein MB, Heppner DG, Fouts TR, Isibasi A & Levine MM (1994). Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. Journal of Infectious Diseases, 169: 927-931.
65. Ulmer JB, Sadoff JC & Liu MA (1996). DNA vaccines. Current Opinion in Immunology, 8: 531-536.
66. Sedegah M, Hedstrom R, Hobart P & Hoffman SL (1994). Protection against malaria by immunisation with plasmid DNA encoding circumsporozoite protein. Proceedings of the National Academy of Sciences, USA, 91: 9866-9870.
67. Doolan DL, Hedstrom RC, Rogers WO, Charoenvit Y, Rogers W, de la Vega M & Hoffman SL (1996). Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1. Journal of Biological Chemistry, 271: 17861-17868.
68. -, and nitric oxide-dependent immunity. Journal of Experimental Medicine, 183: 1739-1746.
69. Xiang Z & Ertl HCJ (1995). Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity, 2: 129-135.